NewYork-Presbyterian Hospital at Columbia University Medical Center
New York, 10032, United States
NCT Number: NCT01448135
The purpose of this pilot study is to assess the efficacy, safety and tolerance profile of the enteral feeding product VITAL AF (a semi-elemental, high protein, and high omega-3 fish oil) when compared to Osmolite 1.2, a standard feeding product in critically ill and/or post surgical patients in the intensive care unit (ICU). If enough patients are recruited, inferences about impact on outcomes may also be drawn.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
New York, 10032, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Semi-elemental, high protein, and high omega-3 fish oil enteral formula
High protein enteral formula
Time frame: Baseline and 21 Days
Measure incidence of diarrhea, nausea, vomiting, increased gastric residual, etc.
Time frame: Baseline and 21 Days
Measurement of volume of feeding product actually delivered to patient is part of the daily flow-sheet data.
Time frame: Baseline and 21 Days
Measure incidence of diarrhea, nausea, vomiting, increased gastric residual, etc.
Columbia University
Other
Pilot Study Evaluating the Efficacy, Tolerance and Safety of VITAL AF (Semi Elemental, High Protein, High Omega 3 Fat Enteral Formula) Versus Osmolite 1.2 (High Protein Enteral Formula) in Multiple ICU Settings (Medical, Surgical, Cardiothoracic)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04612348
Critical Illness, Disease Attributes
Columbus, Ohio, United States
View Trial DetailsNCT03195127
Chronic Disease, Critical Illness
Baltimore, Maryland, United States
View Trial DetailsNCT07020637
Critical Illness, Disease Attributes
Las Vegas, Nevada, United States
View Trial DetailsNCT07579728
Critical Illness, Disease Attributes
Istanbul, Turkey (Türkiye)
View Trial Details